Sort   by:  
 Page size 
GenomicsSGLT2 inhibitors and zebrafish
SGLT2 inhibitors and zebrafish
PRJNA789531 | ENA
ProteomicsProteomic Analysis insights into Potential Mechanism of SGLT2 Inhibitors cardiovascular benefit in Diabetic cardiomyopathy
Diabetic cardiomyopathy (DCM) is one of the major causes of heart failure in diabetic patients, but its pathogenesis remains unclear. Sodium glucose cotransporter 2 inhibitors (SGLT2i) can effectively reduce the risk of cardiovascular death and heart failure in DCM patients, but the underlying mecha...
ORGANISM(S): Rattus norvegicus (Rat) 
2023-03-10 | PXD036090 | Pride
Sglt2 inhibitors Diabetic cardiomyopathy Proteomics 
GenomicsProtective effects of SGLT2 inhibitors in human proximal tubular cells
Protective effects of SGLT2 inhibitors in human proximal tubular cells
PRJNA485256 | ENA
TranscriptomicsSGLT2 inhibitors and zebrafish
The CANVAS program revealed that the SGLT2 inhibitor canagliflozin increases the risk for lower-limb (minor) amputations in type 2 diabetics about a two-fold. On the contrary, the large RCTs with empagliflozin and dapagliflozin did not demonstrate a similar observation. Thus, a question arises wheth...
ORGANISM(S): Danio rerio 
2022-12-31 | GSE191046 | GEO
GenomicsSGLT2 inhibitors suppress epithelial-mesenchymal transition in diabetic podocyte via downregulating IGF1R/PI3K pathway
SGLT2 inhibitors suppress epithelial-mesenchymal transition in diabetic podocyte via downregulating IGF1R/PI3K pathway
PRJNA824061 | ENA
GenomicsSGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth onset type 2 diabetes
SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth onset type 2 diabetes
PRJNA912118 | ENA
TranscriptomicsProtective effects of SGLT2 inhibitors in human proximal tubular cells
Effects of SGLT2 inhibitors on gene expression were evaluated in two independent human proximal tubular cell lines using microarray hybridization analysis followed by pathway analysis as well as qPCR- and ELISA-based verification on mRNA and protein level
ORGANISM(S): Homo sapiens 
2019-01-04 | GSE118337 | GEO
TranscriptomicsSGLT2 inhibitors suppress epithelial-mesenchymal transition in diabetic podocyte via downregulating IGF1R/PI3K pathway
Purpose:Renal injury with the loss of podocyte was characteristic pathology of diabetic nephropathy (DN) and correlated with increased albuminuria. Many studies have found the nephroprotective effect of the novel inhibitors of sodium-glucose cotransporter 2 (SGLT2-is), like Dapagliflozin, delaying t...
ORGANISM(S): Mus musculus 
2022-10-19 | GSE200322 | GEO
ProteomicsMetabolic reconfiguration through SGLT2 inhibition improves metabolic waste excretion
Dapagliflozin is a member of a new class of medication called gliflozins indicated for the treatment of diabetes and has recently been also approved for the treatment of kidney and heart diseases. Gliflozins lower blood glucose levels by inhibition of the sodium glucose co-transporter 2 (SGLT2), whi...
ORGANISM(S): Mus musculus (Mouse) mouse gut metagenome 
2026-02-09 | PXD036817 | Pride
White adipose tissue Kidney Heart Skeletal muscle Lc-ms/ms Dapagliflozin Mouse Tmt Exploris 480 Murine Sglt2 inhibitors Liver Gut microbiome 
ProteomicsCardioprotection by selective SGLT2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
Major clinical trials with sodium glucose co-transporter-2 inhibitors (SGLT-2i) exhibit protective effects against heart failure events, whereas inconsistencies regarding the cardiovascular death outcomes are observed. Therefore, we aimed to compare the selective SGLT-2i empagliflozin (EMPA), dapagl...
ORGANISM(S): Mus Musculus (ncbitaxon:10090) 
2021-12-17 | MSV000088582 | MassIVE
Sort   by:  
 Page size